Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PLSE

Pulse Biosciences Inc

Jun 18 • 04:00PM ET

25.60

+0.15 0.59 %

Healthcare • Medical Instruments & Supplies • USA • Small • NASD

Peers: MMSI TFX BAX BDX MASI BSX EW MDT SYK PLPC

| Held by: VTI IWM VXF IWO VTWO SCHA VHT IWC ITOT ISMD

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.10	Insider Own	73.30%	Shs Outstand	68.23M	Perf Week	-4.80%
Market Cap	1.77B	Forward P/E	-	EPS next Y	-1.20	Insider Trans	1.10%	Shs Float	18.48M	Perf Month	2.61%
Enterprise Value	1.71B	PEG	-	EPS next Q	-0.29	Inst Own	11.45%	Short Float	16.70%	Perf Quarter	14.29%
Income	-74.57M	P/S	2362.36	EPS this Y	-51.54%	Inst Trans	16.88%	Short Ratio	10.01	Perf Half Y	79.90%
Sales	0.75M	P/B	26.34	EPS next Y	-4.96%	ROA	-69.36%	Short Interest	3.09M	Perf YTD	86.45%
Book/sh	0.97	P/C	25.93	EPS next 5Y	-6.05%	ROE	-80.72%	52W High	28.53 -10.27%	Perf Year	70.10%
Cash/sh	0.99	P/FCF	-	EPS past 3/5Y	14.44% 12.82%	ROIC	-103.82%	52W Low	12.56 103.82%	Perf 3Y	308.29%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-20.63% -	Gross Margin	-159.12%	Volatility	8.06% 7.03%	Perf 5Y	47.64%
Dividend TTM	-	EV/Sales	2280.81	EPS Y/Y TTM	-13.79%	Oper. Margin	-10392.14%	ATR (14)	1.82	Perf 10Y	485.81%
Dividend Ex-Date	-	Quick Ratio	7.24	Sales Y/Y TTM	-	Profit Margin	-9929.03%	RSI (14)	53.40	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.26	EPS Q/Q	-9.23%	SMA20	0.97%	Beta	1.66	Target Price	30.67
Payout	-	Debt/Eq	0.11	Sales Q/Q	-	SMA50	9.88%	Rel Volume	1.18	Prev Close	25.45
Employees	116	LT Debt/Eq	0.08	Earnings	May 04 BMO	SMA200	37.49%	Avg Volume	308.30K	Price	25.60
IPO	May 18, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	11.81% 60.00%	Trades		Volume	364,078	Change	0.59%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-04-26	Initiated	Canaccord Genuity	Buy	$32
Jan-30-26	Initiated	Mizuho	Outperform	$25
Jul-07-25	Initiated	Oppenheimer	Outperform	$22
Jul-27-21	Initiated	Stephens	Overweight	$28
Mar-11-21	Initiated	Maxim Group	Buy	$40
Jan-26-21	Reiterated	H.C. Wainwright	Buy	$16 → $40
May-12-20	Upgrade	H.C. Wainwright	Neutral → Buy	$6 → $16
Feb-14-20	Downgrade	H.C. Wainwright	Buy → Neutral	$26 → $6
Feb-25-19	Initiated	H.C. Wainwright	Buy	$27

Jun-10-26 07:00AM	Pulse Biosciences, Inc. Announces Planned Redemption of Warrants (Business Wire)
May-27-26 04:05PM	Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 (Business Wire)
May-12-26 07:00AM	ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million (Business Wire) +22.12%
May-08-26 07:00AM	Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference (Business Wire)
May-04-26 07:00AM	Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results (Business Wire)
01:00PM	Loading…
Apr-25-26 01:00PM	Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse Cardiac Catheter System at Heart Rhythm 2026 (Business Wire)
Apr-20-26 07:00AM	Pulse Biosciences' nPulse Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting (Business Wire)
Apr-17-26 07:00AM	Pulse Biosciences to Host Analyst Event on April 25, 2026 (Business Wire) +14.09%
Apr-10-26 12:12AM	Pulse Biosciences hires Liane Teplitsky as COO (MedTech Dive)
Apr-09-26 07:00AM	Pulse Biosciences Strengthens Executive Leadership Team (Business Wire)
Apr-07-26 07:00AM	Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse Cardiac Catheter System for Atrial Fibrillation (Business Wire) -12.99%
Apr-02-26 04:05PM	Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-17-26 07:00AM	Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data (Business Wire)
Mar-12-26 07:00AM	Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse Technology (Business Wire) +6.45%
Mar-09-26 07:00AM	Pulse Biosciences Announces Clinical Data From nPulse Vybrance System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation (Business Wire)
07:00AM	Loading…
Mar-05-26 07:00AM	Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference (Business Wire)
Mar-04-26 07:00AM	Pulse Biosciences' nPulse Vybrance System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting (Business Wire)
Feb-20-26 04:05PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -14.59% -5.74%
08:30AM	Pulse Biosciences, Inc. Q4 2025 Earnings Call Summary (Moby)
07:00AM	Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference (Business Wire)
12:02AM	Pulse Biosciences Inc (PLSE) Q4 2025 Earnings Call Highlights: Innovations and Challenges in Focus (GuruFocus.com)
Feb-19-26 10:07PM	Pulse Biosciences Q4 Earnings Call Highlights (MarketBeat)
05:45PM	Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results (Business Wire)
Feb-09-26 12:58PM	PLSE Shares Positive First-in-Human nPulse Cardiac Catheter Data (Zacks) +16.67%
09:18AM	What's Going With Pulse Biosciences Stock On Monday? (Benzinga)
Feb-06-26 01:58PM	Pulse Biosciences Heart Device Data Fuels Stock Surge (Benzinga) +51.57%
Feb-05-26 07:00PM	Pulse Biosciences Presents Late-Breaking Data from nPulse Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium (Business Wire) -9.40%
Feb-04-26 04:05PM	Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026 (Business Wire) +7.62%
Feb-03-26 07:00AM	Pulse Biosciences' nPulse Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium (Business Wire)
07:00AM	Loading…
Jan-09-26 07:00AM	Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors (Business Wire)
Jan-06-26 07:00AM	Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium (Business Wire)
Dec-29-25 04:05PM	Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-19-25 04:05PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.12%
10:25AM	PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial (Zacks)
Dec-18-25 07:00AM	Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation (Business Wire)
Dec-10-25 12:40PM	PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor (Zacks)
Dec-09-25 07:00AM	Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse Technology (Business Wire)
Nov-21-25 04:05PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-06-25 04:05PM	Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences (Business Wire)
12:03AM	Pulse Biosciences Inc (PLSE) Q3 2025 Earnings Call Highlights: Regulatory Milestones and Early ... (GuruFocus.com)
Nov-05-25 06:15PM	Pulse Biosciences, Inc (PLSE) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results (Business Wire)
Oct-24-25 07:00AM	Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study (Business Wire)
Oct-22-25 04:05PM	Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025 (Business Wire)
Oct-16-25 07:00AM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-13-25 08:14AM	Pulse Biosciences Unveils Promising First-in-Human Data for nPulse (Zacks)
Oct-10-25 07:00AM	Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting (Business Wire) -8.57%
Oct-07-25 07:00AM	Pulse Biosciences Announces Clinical Data Highlighting its nPulse Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting (Business Wire)
Oct-01-25 01:40PM	Pulse Biosciences, Inc. (PLSE) Advances Cardiac Care with FDA-Approved Atrial Fibrillation Trial (Insider Monkey)
Sep-17-25 07:00AM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-11-25 12:24PM	Pulse Biosciences Gets FDA IDE Nod for Atrial Fibrillation Study (Zacks)
Sep-10-25 07:00AM	Pulse Biosciences' nPulse Technology to be Featured at the American Thyroid Association 2025 Annual Meeting (Business Wire)
Sep-09-25 07:00AM	Pulse wins IDE approval; Galvanize pulls in $100M (MedTech Dive)
Sep-08-25 07:00AM	Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation (Business Wire)
Sep-04-25 07:00AM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-02-25 07:00AM	Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study (Business Wire)
Aug-27-25 12:25PM	PLSE Shares Rise on First-in-Human Data for Thyroid Nodule Treatment (Zacks) -6.27%
Aug-26-25 07:00AM	Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid (Business Wire)
Aug-13-25 03:12AM	Pulse Biosciences Inc (PLSE) Q2 2025 Earnings Call Highlights: Navigating Increased Expenses ... (GuruFocus.com) +11.19%
Aug-12-25 04:05PM	Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results (Business Wire)
Aug-01-25 07:00AM	Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference (Business Wire)
Jul-29-25 04:05PM	Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025 (Business Wire)
Jul-16-25 04:05PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-23-25 04:05PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-09-25 03:41AM	Pulse Biosciences Inc (PLSE) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-08-25 04:05PM	Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results (Business Wire)
May-06-25 04:05PM	Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference (Business Wire)
May-01-25 07:00AM	Pulse Biosciences Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting (Business Wire)
Apr-25-25 04:05PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.06%
Apr-24-25 04:05PM	Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025 (Business Wire) +6.00%
Apr-23-25 07:00AM	Pulse Biosciences Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting (Business Wire)
Apr-10-25 01:00PM	Pulse Biosciences: Some Key Questions Remain Unanswered (Seeking Alpha)
10:36AM	Pulse Biosciences: Interesting Product, But No Revenue Stream (Seeking Alpha)
Mar-28-25 08:10AM	Q4 2024 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +6.00%
03:03AM	Pulse Biosciences Inc (PLSE) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs (GuruFocus.com)
Mar-27-25 07:46PM	Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript (SeekingAlpha)
04:05PM	Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results (Business Wire)
Mar-26-25 04:05PM	Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference (Business Wire)
Mar-07-25 08:00AM	Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025 (Business Wire)
Mar-04-25 08:00AM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-20-25 04:05PM	Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-05-25 09:42AM	Pulse Biosciences names new CFO, continuing string of C-suite changes (MedTech Dive)
Feb-04-25 08:00AM	Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer (Business Wire) +14.84%
Jan-30-25 08:00AM	Pulse Biosciences Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting (Business Wire)
Jan-21-25 01:03PM	Pulse Biosciences touts positive results from PFA early feasibility study (Medical Device Network) +11.16%
07:00AM	Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360 Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium (Business Wire)
Jan-13-25 07:00AM	Pulse Biosciences Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium (Business Wire)
Jan-10-25 08:00AM	Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer (Business Wire)
Jan-03-25 09:00AM	Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) +10.34%
Dec-23-24 04:30PM	Pulse Biosciences, Inc. Announces Planned Redemption of Warrants (Business Wire) +5.34%
Dec-19-24 08:00AM	Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants (Business Wire)
Dec-17-24 08:00AM	Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery (Business Wire)
Oct-31-24 02:25PM	Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association (Business Wire)
01:58PM	Q3 2024 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
05:01AM	Pulse Biosciences Inc (PLSE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Oct-30-24 04:05PM	Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results (Business Wire)
04:02PM	Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology (Business Wire)
Oct-21-24 08:00AM	Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024 (Business Wire)
Aug-21-24 07:55AM	Better Cotton Pakistan, PULSE to boost data transparency in cotton farming (Just Style) +13.76%

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

PresidentMr. Paul Arthur LaViolette M.B.A.

Chief Financial OfficerMr. Jon Skinner

CTO & DirectorMr. Darrin R. Uecker

Chief Operating OfficerMs. Liane Teplitsky

VP of AccountingMr. Steven T. Weber

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LAVIOLETTE PAUL A	Chief Executive Officer	May 11 '26	Buy	19.69	15,000	295,350	15,000	May 11 06:53 PM
DUGGAN ROBERT W	Director	May 11 '26	Buy	19.69	660,233	12,999,988	48,211,433	May 11 06:52 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 18 '26	Option Exercise	1.53	5,000	7,650	48,298	Feb 23 08:55 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 18 '26	Sale	23.64	5,000	118,200	43,298	Feb 23 08:55 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 12 '26	Option Exercise	1.53	20,000	30,600	63,298	Feb 17 08:47 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 13 '26	Option Exercise	1.53	20,000	30,600	63,298	Feb 17 08:47 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 17 '26	Option Exercise	1.53	20,000	30,600	63,298	Feb 17 08:47 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 17 '26	Sale	23.63	20,000	472,600	43,298	Feb 17 08:47 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 13 '26	Sale	23.53	20,000	470,600	43,298	Feb 17 08:47 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 12 '26	Sale	23.37	20,000	467,400	43,298	Feb 17 08:47 PM
KEVIN DANAHY	Officer	Feb 12 '26	Proposed Sale	25.25	50,000	1,262,500		Feb 12 04:27 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 09 '26	Option Exercise	1.53	20,000	30,600	63,298	Feb 11 07:46 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 10 '26	Option Exercise	1.53	20,000	30,600	63,298	Feb 11 07:46 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 11 '26	Option Exercise	1.53	20,000	30,600	63,298	Feb 11 07:46 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 11 '26	Sale	25.20	20,000	504,000	43,298	Feb 11 07:46 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 10 '26	Sale	23.52	20,000	470,400	43,298	Feb 11 07:46 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 09 '26	Sale	21.45	20,000	429,000	43,298	Feb 11 07:46 PM
KEVIN DANAHY	Officer	Feb 09 '26	Proposed Sale	20.75	75,000	1,556,250		Feb 09 04:30 PM
Danahy Kevin Patrick	Chief Commercial Officer	Oct 02 '25	Option Exercise	1.53	4,600	7,038	47,898	Oct 07 07:18 PM
Danahy Kevin Patrick	Chief Commercial Officer	Oct 02 '25	Sale	18.53	4,600	85,238	43,298	Oct 07 07:18 PM
Danahy Kevin Patrick	Chief Commercial Officer	Sep 18 '25	Option Exercise	1.53	20,000	30,600	63,298	Sep 22 09:24 PM
Danahy Kevin Patrick	Chief Commercial Officer	Sep 19 '25	Option Exercise	1.53	400	612	43,698	Sep 22 09:24 PM
Danahy Kevin Patrick	Chief Commercial Officer	Sep 18 '25	Sale	18.49	20,000	369,800	43,298	Sep 22 09:24 PM
Danahy Kevin Patrick	Chief Commercial Officer	Sep 19 '25	Sale	18.48	400	7,392	43,298	Sep 22 09:24 PM
UECKER DARRIN	Chief Technology Officer	Sep 17 '25	Option Exercise	4.00	181,534	726,136	284,406	Sep 18 08:44 PM
UECKER DARRIN	Chief Technology Officer	Sep 16 '25	Option Exercise	4.00	25,000	100,000	147,872	Sep 18 08:44 PM
UECKER DARRIN	Chief Technology Officer	Sep 16 '25	Sale	16.28	25,000	407,000	122,872	Sep 18 08:44 PM
UECKER DARRIN	Chief Technology Officer	Sep 17 '25	Sale	16.21	20,000	324,200	122,872	Sep 18 08:44 PM
KEVIN DANAHY	Officer	Sep 18 '25	Proposed Sale	16.27	25,000	406,750		Sep 18 04:29 PM
UECKER DARRIN	Chief Technology Officer	Sep 11 '25	Option Exercise	4.00	25,000	100,000	147,872	Sep 15 09:09 PM
UECKER DARRIN	Chief Technology Officer	Sep 12 '25	Option Exercise	4.00	25,000	100,000	147,872	Sep 15 09:09 PM
UECKER DARRIN	Chief Technology Officer	Sep 15 '25	Option Exercise	4.00	25,000	100,000	147,872	Sep 15 09:09 PM
UECKER DARRIN	Chief Technology Officer	Sep 15 '25	Sale	15.77	25,000	394,250	122,872	Sep 15 09:09 PM
UECKER DARRIN	Chief Technology Officer	Sep 11 '25	Sale	14.78	25,000	369,500	122,872	Sep 15 09:09 PM
UECKER DARRIN	Chief Technology Officer	Sep 12 '25	Sale	14.32	25,000	358,000	122,872	Sep 15 09:09 PM
DUGGAN ROBERT W	Director	Sep 10 '25	Buy	14.66	34,659	508,101	47,551,200	Sep 12 08:14 PM
DARRIN UECKER	Director	Sep 11 '25	Proposed Sale	14.77	120,000	1,772,400		Sep 11 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PLSE

Pulse Biosciences Inc

Upgrade your Finviz experience